Toxic Leukoencephalopathy following Fludarabine-Associated Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 3, 2011, Pages 300-308

  Beitinjaneh, Amer ^a   McKinney, Alexander M ^a   Cao, Qing ^a   Weisdorf, Daniel J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Fludarabine; Hematopoietic cell transplantation; Posterior reversible encephalopathy syndrome; Toxic leukoencephalopathy

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ADULT; AGED; APLASTIC ANEMIA; BLURRED VISION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; CONSCIOUSNESS LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSARTHRIA; FANCONI ANEMIA; FEMALE; GRAFT VERSUS HOST REACTION; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LEUKOENCEPHALOPATHY; MALE; MENTAL HEALTH; NEUROLOGIC DISEASE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT SAFETY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGNOSIS; REVIEW; RISK FACTOR; SEIZURE; SUBCORTEX; SYMPTOM; TOXIC LEUKOENCEPHALOPATHY; VISUAL DISORDER; WHITE MATTER;

ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKOENCEPHALOPATHIES; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; PRODRUGS; VIDARABINE;

EID: 79551681652     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.04.003     Document Type: Review

References (37)

1. Zaucha-Prazmo A., Jasinski M., Drabko K., Choma M., Wojcik B., Kowalczyk J.R. Neurologic complications in children after hemaopoietic stem cell transplantation: a single-center experience. Transplant Proc 2007, 39:2905-2907.
2. Sostak P., Padovan C.S., Yousry T.A., Ledderose G., Kolb H.J., Straube A. Prospective evaluation of neurological complications after allogeneic bone marrow transplantation. Neurology 2003, 60:842-848.
3. Iguchi A., Kobayashi R., Yoshida M., et al. Neurological complications after stem cell transplantation in childhood. Bone Marrow Transplant 1999, 24:647-652.
4. Gallardo D., Ferra C., Berlanga J.J., et al. Neurologic complications after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996, 18:1135-1139.
5. Siegal D., Keller A., Xu W., et al. Central nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significance. Biol Blood Marrow Transplant 2007, 13:1369-1379.
6. McKinney A.M., Short J., Truwit C.L., et al. Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol 2007, 189:904-912.
7. McKinney A.M., Kieffer S.A., Paylor R.T., SantaCruz K.S., Kendi A., Lucato L. Acute toxic leukoencephalopathy: potential for reversibility clinically and on MRI with diffusion-weighted and FLAIR imaging. AJR Am J Roentgenol 2009, 193:192-206.
8. Cheson B.D., Vena D.A., Foss F.M., Sorensen J.M. Neurotoxicity of purine analogs: a review. J Clin Oncol 1994, 12:2216-2228.
9. Warrell R.P., Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 1986, 4:74-79.
10. Von Hoff D.D. Phase I clinical trials with fludarabine phosphate. Semin Oncol 1990, 17:33-38.
11. Chun H.G., Leyland-Jones B.R., Caryk S.M., Hoth D.F. Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep 1986, 70:1225-1228.
12. Merkel D.E., Griffin N.L., Kagan-Hallet K., Von Hoff D.D. Central nervous system toxicity with fludarabine. Cancer Treat.Rep 1986, 70:1449-1450.
13. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). August 9, 2006.
14. Filley C.M. Toxic leukoencephalopathy. Clin Neuropharmacol 1999, 22:249-260.
15. Moore-Maxwell C.A., Datto M.B., Hulette C.M. Chemotherapy-induced toxic leukoencephalopathy causes a wide range of symptoms: a series of four autopsies. Mod Pathol 2004, 17:241-247.
16. Perry A., Schmidt R.E. Cancer therapy-associated CNS neuropathology: an update and review of the literature. Acta Neuropathol 2006, 111:197-212.
17. Boogerd W., vd Sande J.J., Moffie D. Acute fever and delayed leukoencephalopathy following low dose intraventricular methotrexate. J Neurol Neurosurg Psychiatry 1988, 51:1277-1283.
18. Asato R., Akiyama Y., Ito M., et al. Nuclear magnetic resonance abnormalities of the cerebral white matter in children with acute lymphoblastic leukemia and malignant lymphoma during and after central nervous system prophylactic treatment with intrathecal methotrexate. Cancer 1992, 70:1997-2004.
19. Schwartz R.B., Jones K.M., Kalina P., et al. Hypertensive encephalopathy: findings on CT, MR imaging, and SPECT imaging in 14 cases. AJR Am J Roentgenol 1992, 159:379-383.
20. Hinchey J., Chaves C., Appignani B., et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996, 334:494-500.
21. Schiff D., Lopes M.B. Neuropathological correlates of reversible posterior leukoencephalopathy. Neurocrit Care 2005, 2:303-305.
22. Bartynski W.S., Zeigler Z., Spearman M.P., Lin L., Shadduck R.K., Lister J. Etiology of cortical and white matter lesions in cyclosporin-A and FK-506 neurotoxicity. AJNR Am J Neuroradiol 2001, 22:1901-1914.
23. Bartynski W.S., Grabb B.C., Zeigler Z., Lin L., Andrews D.F. Watershed imaging features and clinical vascular injury in cyclosporin A neurotoxicity. J Comput Assist Tomogr 1997, 21:872-880.
24. Lai R., Abrey L.E., Rosenblum M.K., DeAngelis L.M. Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 2004, 62:451-456.
25. Saykin A.J., Ahles T.A., McDonald B.C. Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsychiatry 2003, 8:201-216.
26. Akiba T., Okeda R., Tajima T. Metabolites of 5-fluorouracil, alpha-fluoro-beta-alanine and fluoroacetic acid, directly injure myelinated fibers in tissue culture. Acta Neuropathol 1996, 92:8-13.
27. Schaefer P.W., Copen W.A., Lev M.H., Gonzalez R.G. Diffusion-weighted imaging in acute stroke. Neuroimaging Clin N Am 2005, 15:503-530. ix-x.
28. Baehring J.M., Fulbright R.K. Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients. J Neurol Neurosurg Psychiatry 2008, 79:535-539.
29. Wiederrecht G., Lam E., Hung S., Martin M., Sigal N. The mechanism of action of FK-506 and cyclosporin A. Ann NY Acad Sci 1993, 696:9-19.
30. Edvinsson L., Owman C., Sjoberg N.O. Autonomic nerves, mast cells, and amine receptors in human brain vessels. A histochemical and pharmacological study. Brain Res 1976, 115:377-393.
31. Schwartz R.B., Bravo S.M., Klufas R.A., et al. Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. AJR Am J Roentgenol 1995, 165:627-631.
32. Wijdicks E.F., Wiesner R.H., Krom R.A. Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression. Neurology 1995, 45:1962-1964.
33. Badagnani I., Chan W., Castro R.A., et al. Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3). Pharmacogenomics J 2005, 5:157-165.
34. Martell R.E., Peterson B.L., Cohen H.J., et al. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. Cancer Chemother Pharmacol 2002, 50:37-45.
35. Adjei A.A., Dagnino L., Wong M.M., Paterson A.R. Protection against fludarabine neurotoxicity in leukemic mice by the nucleoside transport inhibitor nitrobenzylthioinosine. Cancer Chemother Pharmacol 1992, 31:71-75.
36. Cohen R.B., Abdallah J.M., Gray J.R., Foss F. Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann Intern Med 1993, 118:114-116.
37. Sorensen J.M., Vena D.A., Fallavollita A., Chun H.G., Cheson B.D. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: 5-year follow-up report. J Clin Oncol 1997, 15:458-465.